The global antibody discovery market size is predicted to increase from USD 8.27 billion in 2024, grow to USD 9.06 billion in 2025, and is anticipated to reach around USD 20.50 billion by 2034, poised to grow at a CAGR of 9.5% between 2024 and 2034. The North America antibody discovery market size is calculated at USD 2.98 billion in 2024 and is estimated to grow at the fastest CAGR of 9.65% during the forecast year.
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology (Premium Insights)
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Antibody Discovery Market
5.1. COVID-19 Landscape: Antibody Discovery Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Antibody Discovery Market, By Methods
8.1. Antibody Discovery Market, by Methods, 2024-2034
8.1.1 Phage Display
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. Hybridoma
8.1.2.1. Market Revenue and Forecast (2021-2034)
8.1.3. Others
8.1.3.1. Market Revenue and Forecast (2021-2034)
Chapter 9. Global Antibody Discovery Market, By Antibody Type
9.1. Antibody Discovery Market, by Antibody Type, 2024-2034
9.1.1. Humanized Antibody
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Human Antibody
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Chimeric Antibody
9.1.3.1. Market Revenue and Forecast (2021-2034)
9.1.4. Murine Antibody
9.1.4.1. Market Revenue and Forecast (2021-2034)
Chapter 10. Global Antibody Discovery Market, By End Users
10.1. Antibody Discovery Market, by End Users, 2024-2034
10.1.1. Pharmaceutical and Biotechnology industry
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Research laboratory
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Academic laboratory
10.1.3.1. Market Revenue and Forecast (2021-2034)
Chapter 11. Global Antibody Discovery Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Methods (2021-2034)
11.1.2. Market Revenue and Forecast, by Antibody Type (2021-2034)
11.1.3. Market Revenue and Forecast, by End Users (2021-2034)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Methods (2021-2034)
11.1.4.2. Market Revenue and Forecast, by Antibody Type (2021-2034)
11.1.4.3. Market Revenue and Forecast, by End Users (2021-2034)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Methods (2021-2034)
11.1.5.2. Market Revenue and Forecast, by Antibody Type (2021-2034)
11.1.5.3. Market Revenue and Forecast, by End Users (2021-2034)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Methods (2021-2034)
11.2.2. Market Revenue and Forecast, by Antibody Type (2021-2034)
11.2.3. Market Revenue and Forecast, by End Users (2021-2034)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Methods (2021-2034)
11.2.4.2. Market Revenue and Forecast, by Antibody Type (2021-2034)
11.2.4.3. Market Revenue and Forecast, by End Users (2021-2034)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Methods (2021-2034)
11.2.5.2. Market Revenue and Forecast, by Antibody Type (2021-2034)
11.2.5.3. Market Revenue and Forecast, by End Users (2021-2034)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Methods (2021-2034)
11.2.6.2. Market Revenue and Forecast, by Antibody Type (2021-2034)
11.2.6.3. Market Revenue and Forecast, by End Users (2021-2034)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Methods (2021-2034)
11.2.7.2. Market Revenue and Forecast, by Antibody Type (2021-2034)
11.2.7.3. Market Revenue and Forecast, by End Users (2021-2034)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Methods (2021-2034)
11.3.2. Market Revenue and Forecast, by Antibody Type (2021-2034)
11.3.3. Market Revenue and Forecast, by End Users (2021-2034)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Methods (2021-2034)
11.3.4.2. Market Revenue and Forecast, by Antibody Type (2021-2034)
11.3.4.3. Market Revenue and Forecast, by End Users (2021-2034)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Methods (2021-2034)
11.3.5.2. Market Revenue and Forecast, by Antibody Type (2021-2034)
11.3.5.3. Market Revenue and Forecast, by End Users (2021-2034)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Methods (2021-2034)
11.3.6.2. Market Revenue and Forecast, by Antibody Type (2021-2034)
11.3.6.3. Market Revenue and Forecast, by End Users (2021-2034)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Methods (2021-2034)
11.3.7.2. Market Revenue and Forecast, by Antibody Type (2021-2034)
11.3.7.3. Market Revenue and Forecast, by End Users (2021-2034)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Methods (2021-2034)
11.4.2. Market Revenue and Forecast, by Antibody Type (2021-2034)
11.4.3. Market Revenue and Forecast, by End Users (2021-2034)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Methods (2021-2034)
11.4.4.2. Market Revenue and Forecast, by Antibody Type (2021-2034)
11.4.4.3. Market Revenue and Forecast, by End Users (2021-2034)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Methods (2021-2034)
11.4.5.2. Market Revenue and Forecast, by Antibody Type (2021-2034)
11.4.5.3. Market Revenue and Forecast, by End Users (2021-2034)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Methods (2021-2034)
11.4.6.2. Market Revenue and Forecast, by Antibody Type (2021-2034)
11.4.6.3. Market Revenue and Forecast, by End Users (2021-2034)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Methods (2021-2034)
11.4.7.2. Market Revenue and Forecast, by Antibody Type (2021-2034)
11.4.7.3. Market Revenue and Forecast, by End Users (2021-2034)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Methods (2021-2034)
11.5.2. Market Revenue and Forecast, by Antibody Type (2021-2034)
11.5.3. Market Revenue and Forecast, by End Users (2021-2034)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Methods (2021-2034)
11.5.4.2. Market Revenue and Forecast, by Antibody Type (2021-2034)
11.5.4.3. Market Revenue and Forecast, by End Users (2021-2034)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Methods (2021-2034)
11.5.5.2. Market Revenue and Forecast, by Antibody Type (2021-2034)
11.5.5.3. Market Revenue and Forecast, by End Users (2021-2034)
Chapter 12. Company Profiles
12.1. Danaher Corporation
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Eurofins Scientific
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Evotec
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. Twist Bioscience
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Charles River Laboratories
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Genscript Technology Corporation
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Biocytogen
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Sartorius AG
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Fairjourney Biologics S.A
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Creative Biolabs
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Report Description
Get a Sample